You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 124 No. 11, November 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (61)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Head & Neck Cancer
 •Neoplasms of Head & Neck
 •Radiation Therapy
 •Surgery
 •Laser Surgery
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Transoral Laser Surgery of Supraglottic Cancer

Follow-up of 141 Patients

Heinrich Iro, MD; Frank Waldfahrer, MD; Annelore Altendorf-Hofmann, MD; Manfred Weidenbecher, MD; Rolf Sauer, MD; Wolfgang Steiner, MD

Arch Otolaryngol Head Neck Surg. 1998;124:1245-1250.

Objective  To determine the role of transoral laser resection of supraglottic carcinomas.

Design  Retrospective unicenter study of the oncologic results of transoral carbon dioxide laser microsurgery for supraglottic carcinomas performed between February 1979 and December 1993. Median follow-up was 37 months.

Setting  University hospital academic tertiary referral center.

Patients  We reviewed the medical records of 141 patients (a consecutive sample of 131 men and 10 women; mean age, 60 years) with histologically proven supraglottic carcinomas undergoing transoral laser surgery, possibly in combination with neck dissection or radiotherapy. Stage distribution of patients was as follows: stage I, 23.4%; stage II, 25.5%; stage III, 16.3%; and stage IV, 34.8% (according to the Union Internationale Contre le Cancer staging system).

Main Outcome Measures  Recurrence-free survival rates and local and regional recurrence rates.

Results  Five-year recurrence-free survival rates were as follows: the whole case load, 65.7%; stage I, 85.0%; stage II, 62.6%; stage III, 74.2%; and stage IV, 45.3%, according to the Union Internationale Contre le Cancer staging system. The local and regional recurrence rates were 16.3% and 9.9%, respectively.

Conclusions  The oncologic results of transoral carbon dioxide laser surgery are satisfying if clean surgical margins (R0 resection) can be reached. In patients in whom tumor-free margins are not achieved (R1 and R2 resection) and transoral revision is not possible, transcervical procedures (partial or total laryngectomy) should be performed. The indication for transoral supraglottic laryngectomy in T3 lesions should be considered with restraint.


From the Department of Otorhinolaryngology–Head and Neck Surgery, Saarland University, Homburg (Drs Iro and Waldfahrer); the Tumor Registry (Dr Altendorf-Hofmann) and the Departments of Otorhinolaryngology– Head and Neck Surgery (Dr Weidenbecher), and Radiation Oncology (Dr Sauer), University of Erlangen-Nuremberg, Erlangen; and the Department of Otorhinolaryngology–Head and Neck Surgery, University of Goettingen, Goettingen (Dr Steiner), Germany.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Transoral Laser Microsurgery for Advanced Laryngeal Cancer
Hinni et al.
Arch Otolaryngol Head Neck Surg 2007;133:1198-1204.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
Pfister et al.
JCO 2006;24:3693-3704.
ABSTRACT | FULL TEXT  

Concurrent Chemoradiotherapy as the Most Appropriate Treatment for Most T3 Laryngeal Carcinomas
Enepekides
Arch Otolaryngol Head Neck Surg 2005;131:815-818.
FULL TEXT  

Nonsurgical Treatment of Laryngeal Cancer
Weinstein et al.
NEJM 2004;350:1049-1053.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.